Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
News
BILIARY ATRESIA
NewsMaralixibat reduces itch in children with biliary atresia: Case series
Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children with biliary atresia, including…
On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed…
CHOLANGITIS
NewsPBC treatment Livdelzi shows benefits for 2.5 years in Phase 3 trial
After 2.5 years of Livdelzi (seladelpar) treatment, more than 4 in 5 adults with primary biliary cholangitis (PBC) saw meaningful reductions in liver…
CHOLESTASIS
NewsBylvay eases itch over long term in PFIC, Alagille syndrome patients
Nearly 1.5 years of treatment with Bylvay (odevixibat) effectively reduces itching and liver damage markers, and improves growth and sleep in people with…
FATTY LIVER DISEASE
NewsFatty liver disease affects 45% of teens, adults in US, Hispanics most
About 45% of teens and adults in the U.S. have some form of fatty liver disease, with Hispanic populations being more affected than other…
ALAGILLE SYNDROME
NewsCase study highlights challenges to diagnosis of Alagille syndrome
A diagnosis of Alagille syndrome can be challenging, particularly in areas that lack access to genetic testing and specialized imaging, a case report from…
HEPATITIS
NewsStudy uncovers how hepatitis E can lead to kidney damage
Researchers have identified a possible mechanism by which infection with the hepatitis E virus (HEV), a known cause of liver inflammation, can lead to…
CHOLANGITIS
NewsFDA rejects full approval of Ocaliva as second-line PBC treatment
The U.S. Food and Drug Administration (FDA) has turned down a request by Intercept Pharmaceuticals for the full approval of Ocaliva (obeticholic acid) as…
CHOLESTASIS
NewsHigh urine protein may be common sign of ICP, study finds
About 1 in 3 pregnant women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver complication, had proteinuria, or high levels of…
Recent Posts
- Lonafarnib combos offer hope for hepatitis D care, per gobal trial data
- Scientists ID, test 2 immune proteins as possible therapeutic targets in PBC
- New optimized treatment found to ease chronic itch in liver disease rat model
- What the recent protein craze means for those of us with liver disease
- A ‘graduation’ photo prompts reflection on a family’s Alagille journey